DescriptionCurator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=317cc880-73fe-4561-897e-41489108b3ba
http://www.drugbank.ca/drugs/DB00803
http://www.rxlist.com/coly-mycin-s-otic-drug.htm
https://www.niaid.nih.gov/topics/antimicrobialResistance/Pages/colistin.aspx
Curator's Comment: Description was created based on several sources, including:
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=317cc880-73fe-4561-897e-41489108b3ba
http://www.drugbank.ca/drugs/DB00803
http://www.rxlist.com/coly-mycin-s-otic-drug.htm
https://www.niaid.nih.gov/topics/antimicrobialResistance/Pages/colistin.aspx
Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. It is a cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C). Colistin was first isolated in Japan in 1949 from a flask of fermenting Bacillus polymyxa var. colistinus and became available for clinical use in 1959. The following local adverse events have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, etc. Healthcare providers had largely stopped using colistin in the 1970s because of its toxicity. However, with antibacterial resistance on the rise, colistin is increasingly being used today to treat severe, multidrug-resistant Gram-negative bacterial infections, particularly among intensive care-based patients. The problem with re-introducing an older drug, such as colistin, though, is that techniques for evaluating new drugs have evolved since the 1950s, and therefore, little is known about the dose needed to effectively fight infection while limiting the potential emergence of antimicrobial resistance and reducing potentially toxic side effects. More data are needed to guide optimal use of these older medications. An international team of NIAID-funded researchers is making progress in obtaining better dosing information about colistin and how best to use the antibiotic to treat Gram-negative bacterial infections. Resistance to colistin is rare. The first colistin-resistance gene that is carried in a plasmid and can be transferred between bacterial strains was described in 2016. This plasmid-borne mcr-1 gene has since been isolated in China, Europeand the United States.
Originator
Sources: http://www.cfmedicine.com/cfdocs/cftext/colistin.htm
Curator's Comment: Colistin was first discovered by Koyama et al. in 1949.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Bacterial outer membrane Sources: http://www.drugbank.ca/drugs/DB00803 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | COLY-MYCIN S Approved UseCortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. Launch Date1962 |
|||
Curative | COLY-MYCIN S Approved UseCortisporin®-TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. Launch Date1962 |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Therapy with Coly-Mycin S (Colistin-containing suspension) should be limited to 10 days.
For adults, 5 drops of the suspension into the affected ear 3 or 4 times daily. For pediatric patients, 4 drops are suggested.
Route of Administration:
Otic (auricular)
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4015067
Lethal concentrations of colistin of 50 and 100 µg/ml caused about 90 and 99% cell death, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78160
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1148001
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
CHEMBL2221249
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
1264-72-8
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
SUB01431MIG
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
WP15DXU577
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
759273
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
WP15DXU577
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
215-034-3
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
DB00803
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
m3733
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID3045352
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | |||
|
2710
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
C386
Created by
admin on Fri Dec 15 15:56:49 GMT 2023 , Edited by admin on Fri Dec 15 15:56:49 GMT 2023
|
PRIMARY |
All of the following components must be present:
ACTIVE MOIETY
SUBSTANCE RECORD